<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">54056</article-id><article-id pub-id-type="doi">10.7554/eLife.54056</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Vascular permeability in retinopathy is regulated by VEGFR2 Y949 signaling to VE-cadherin</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-166607"><name><surname>Smith</surname><given-names>Ross</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-167417"><name><surname>Ninchoji</surname><given-names>Takeshi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-167416"><name><surname>Gordon</surname><given-names>Emma</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-167415"><name><surname>André</surname><given-names>Helder</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-147562"><name><surname>Dejana</surname><given-names>Elizabetta</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-41846"><name><surname>Vestweber</surname><given-names>Dietmar</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3517-732X</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-167414"><name><surname>Kvanta</surname><given-names>Anders</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-57798"><name><surname>Claesson-Welsh</surname><given-names>Lena</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4275-2000</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Immunology, Genetics and Pathology</institution>, <institution>Uppsala University</institution>, <addr-line><named-content content-type="city">Uppsala</named-content></addr-line>, <country>Sweden</country></aff><aff id="aff2"><institution content-type="dept">Department of Clinical Neuroscience, Section for Ophthalmology and Vision</institution>, <institution>Karolinska Institute</institution>, <addr-line><named-content content-type="city">Stockholm</named-content></addr-line>, <country>Sweden</country></aff><aff id="aff3"><institution content-type="dept">Department of Immunology, Genetics and Pathology</institution>, <institution>Uppsala University</institution>, <addr-line><named-content content-type="city">Uppsala</named-content></addr-line>, <country>Sweden</country></aff><aff id="aff4"><institution content-type="dept">Department of Vascular Cell Biology</institution>, <institution>Max Planck Institute for Molecular Biomedicine</institution>, <addr-line><named-content content-type="city">Münster</named-content></addr-line>, <country>Germany</country></aff><aff id="aff5"><institution content-type="dept">Neuroscience, Section for Ophthalmology and Vision</institution>, <institution>Karolinska Institute</institution>, <addr-line><named-content content-type="city">Stockholm</named-content></addr-line>, <country>Sweden</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-56874"><name><surname>Bautch</surname><given-names>Victoria L</given-names></name><role>Reviewing editor</role><aff><institution>University of North Carolina, Chapel Hill</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>lena.welsh@igp.uu.se</email> (LC);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>21</day><month>04</month><year>2020</year></pub-date><volume>9</volume><elocation-id>e54056</elocation-id><history><date date-type="received"><day>30</day><month>11</month><year>2019</year></date><date date-type="accepted"><day>05</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Smith et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Smith et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-54056-v1.pdf"/><abstract><p>Edema stemming from leaky blood vessels is common in eye diseases such as age-related macular degeneration and diabetic retinopathy. Whereas therapies targeting vascular endothelial growth factor A (VEGFA) can suppress leakage, side-effects include vascular rarefaction and geographic atrophy. By challenging mouse models representing different steps in VEGFA/VEGF receptor 2 (VEGFR2)-induced vascular permeability, we show that targeting signaling downstream of VEGFR2 pY949 limits vascular permeability in retinopathy induced by high oxygen or by laser-wounding. Although suppressed permeability is accompanied by reduced pathological neoangiogenesis in oxygen-induced retinopathy, similarly sized lesions leak less in mutant mice, separating regulation of permeability from angiogenesis,. Strikingly, vascular endothelial (VE)-cadherin phosphorylation at the Y685, but not Y658, residue is reduced when VEGFR2 pY949 signaling is impaired. These findings support a mechanism whereby VE-cadherin Y685 phosphorylation is selectively associated with excessive vascular leakage. Therapeutically, targeting VEGFR2-regulated VE-cadherin phosphorylation could suppress edema while leaving other VEGFR2-dependent functions intact.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000923</institution-id><institution>Australian Research Council</institution></institution-wrap></funding-source><award-id>DE170100167</award-id><principal-award-recipient><name><surname>Gordon</surname><given-names>Emma</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004359</institution-id><institution>Vetenskapsrådet</institution></institution-wrap></funding-source><award-id>2015-02375</award-id><principal-award-recipient><name><surname>Claesson-Welsh</surname><given-names>Lena</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004063</institution-id><institution>Knut och Alice Wallenbergs Stiftelse</institution></institution-wrap></funding-source><award-id>2015.0030</award-id><principal-award-recipient><name><surname>Claesson-Welsh</surname><given-names>Lena</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004063</institution-id><institution>Knut och Alice Wallenbergs Stiftelse</institution></institution-wrap></funding-source><award-id>2015.0275</award-id><principal-award-recipient><name><surname>Claesson-Welsh</surname><given-names>Lena</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001674</institution-id><institution>Fondation Leducq</institution></institution-wrap></funding-source><award-id>17 CVD 03</award-id><principal-award-recipient><name><surname>Claesson-Welsh</surname><given-names>Lena</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004097</institution-id><institution>Fondation ARC pour la Recherche sur le Cancer</institution></institution-wrap></funding-source><award-id>AIRC IG 18683</award-id><principal-award-recipient><name><surname>Dejana</surname><given-names>Elizabetta</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Mouse husbandry and oxygen-induced retinopathy (OIR) challenge took place at Uppsala University, and the University board of animal experimentation approved all animal work for those studies (Permit Number 5.8.18-06789-2018). Choroidal neovascularization (CNV) experiments took place at Karolinska Institutet, St. Erik Eye Hospital, Stockholm; the procedures were approved by the Stockholm's Committee for Ethical Animal Research (Permit Number Dnr 49/15). Animal handling was in accordance to the ARVO statement for the Use of Animals in Ophthalmologic and Vision Research.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Text files containing the ImageJ macros used for automatic detection of microspheres in Figures 1 and 2 are provided.</p></sec><supplementary-material><ext-link xlink:href="elife-54056-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>